Cantor Fitzgerald Forecasts Strong Price Appreciation for Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics (NASDAQ:CAPR) had its price objective raised by Cantor Fitzgerald from $25.00 to $30.00 in a research report report published on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

Other equities research analysts have also issued reports about the stock. Piper Sandler started coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price on the stock. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, October 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Trading Up 0.6 %

NASDAQ:CAPR opened at $18.61 on Thursday. The stock’s 50-day moving average is $15.21 and its 200-day moving average is $8.50. Capricor Therapeutics has a 1-year low of $2.87 and a 1-year high of $23.40. The stock has a market cap of $845.01 million, a P/E ratio of -17.56 and a beta of 4.00.

Insiders Place Their Bets

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon purchased 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The shares were purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets bought a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $40,000. Main Street Financial Solutions LLC raised its holdings in shares of Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new position in Capricor Therapeutics in the 3rd quarter valued at about $133,000. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $161,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.